Edgar Filing: IMMUNOGEN INC - Form 4

IMMUNOGEN I Form 4	NC									
November 12, 20	14									
FORM 4	N.T.	PPROVAL								
	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549					N OMB Number:	3235-0287			
Check this box if no longer subject to Section 16. Form 4 or		1ENT OF	F CHAN	WNERSHIP OF	Expires: Estimated a burden hou response	urs per				
Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940										
(Print or Type Respon	nses)									
1. Name and Address of Reporting Person <u>*</u> PIEN HOWARD H			2. Issuer Name and Ticker or Trading Symbol IMMUNOGEN INC [IMGN]				5. Relationship of Reporting Person(s) to Issuer			
(Last) ((First) (1	Middle)	3. Date of Earliest Transaction			(Check all applicable)				
6 CARRIAGE HOUSE COURT			(Month/Day/Year) 11/11/2014			X_ Director 10% Owner Officer (give title Other (specify below)				
(Street)			4. If Amendment, Date Original Filed(Month/Day/Year)			6. Individual or Joint/Group Filing(CheckApplicable Line)_X_ Form filed by One Reporting Person				
CHERRY HILL,	, NJ 08003						Form filed by Person	More than One Ro	eporting	
(City) ((State)	(Zip)	Tab	ole I - Non-J	Derivativ	e Securities A	Acquired, Disposed	of, or Beneficia	lly Owned	
	ansaction Date th/Day/Year)	2A. Deeme Execution any (Month/Da	Date, if	3. Transactic Code (Instr. 8)	Dispose (Instr. 3	d (A) or d of (D) , 4 and 5) (A) or	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code V	Amoun	t (D) Price				
Reminder: Report on	a separate line	for each cla	ass of sec	urities bene	-	-	-			
					info requ	rmation con lired to resp lays a curre	spond to the colle tained in this forn ond unless the fo ntly valid OMB co	n are not rm	GEC 1474 (9-02)	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and Expiration	7. Title and Amour
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transactio	orDerivative	Date	Underlying Securit
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8)	Acquired (A)		

Edgar Filing: IMMUNOGEN INC - Form 4

	Derivative Security				or Dispose (D) (Instr. 3, 4 and 5)					
			Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amc or Num of Sl
Deferred Share Unit	\$ 0 <u>(1)</u>	11/11/2014	А		3,000		02/01/2015(3)(2)	<u>(2)</u>	Common Stock (2)	3,0
Stock option (right to buy)	\$ 10.1	11/11/2014	A		10,000		02/01/2015 <u>(4)</u>	11/11/2024	Common Stock	10,

Reporting Owners

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
PIEN HOWARD H 6 CARRIAGE HOUSE COURT CHERRY HILL, NJ 08003	Х						
Signatures							
/s/ Craig Barrows, attorney in fact	11/12/2014						
**Signature of Reporting Person		Date					

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis.
- (2) The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors.
- (3) The deferred share units vest ratably over a one year period in quarterly increments beginning on February 1, 2015, contingent upon the individual remaining a director as of each vesting date.

Exercisable as to 2,500 shares commencing on February 1, 2015, 2,500 shares commencing on May 1, 2015, 2,500 shares commencing(4) on August 1, 2015 and 2,500 shares commencing on November 1, 2015, contingent upon the individual remaining a director as of each vesting date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.